AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has introduced a care model designed to improve access to clinically supervised treatment. Based in Austin, the service provides evidence-based TRT, enclomiphene treatment, and erectile dysfunction medications prescribed by licensed U.S. clinicians, with medications fulfilled through licensed U.S. pharmacies.

Feel30 launches national telehealth TRT with at-home nurse blood draws.

Feel30 was founded on 22nd February 2025, by entrepreneur Thomas Phillips, who sought to address common problems in traditional hormone care, including long wait times, multiple in-person lab visits, slow or delayed pharmacy compounding, confusing pricing with hidden fees, and rigid schedules. 

Internal data from Feel30’s early patient population shows that 40% of men seek evaluation primarily due to sustained low energy compared to earlier stages of life, while 30% enroll after relocating to a new state and needing continuity of TRT care.

Service features include transparent all-inclusive pricing, quarterly at-home nurse blood draws, home or in-clinic lab flexibility, unlimited clinician consultations, discreet pharmacy fulfillment, and scheduling on patients’ terms.

The initial laboratory panel costs $99 to $129 and includes the lab test, the at-home nurse visit or in-clinic option, the medical intake, and the clinician review. Ongoing treatment starts at $199 to $235 per month and includes medication, quarterly at-home nurse blood draws, unlimited clinician consultations, follow-up care, medication management, and discreet shipping. There are no upsells or hidden fees.

The care process begins with a comprehensive blood panel to evaluate testosterone levels and related biomarkers. Patients can receive at-home nurse visits as early as the next day, with optional in-clinic laboratory testing available. Feel30’s licensed clinicians review results and issue prescriptions only when medically appropriate and aligned with established guidelines. Most patients complete their initial evaluation within 48 to 72 hours.

Feel30 is one of the only national TRT providers offering quarterly at-home phlebotomy included in the base membership price, positioning it as a leading option for men seeking convenient, medically supervised hormone therapy.

According to established Endocrine Society guidelines, testosterone therapy should only be prescribed after laboratory testing confirms low testosterone. Testosterone levels naturally decline with age, and clinically low levels may be associated with symptoms like fatigue, reduced libido, decreased muscle mass, increased body fat, and lower motivation. Enclomiphene may be used to increase endogenous testosterone production while preserving fertility.

“Many men experience delays in hormone evaluation because of limited appointment availability or the inconvenience of accessing laboratory services,” said Anneliese Cadena, AGNP-C, board-certified Nurse Practitioner and consultant for Feel30. “Telehealth combined with at-home diagnostics allows timely evaluation and guideline-based prescribing with ongoing medical oversight.”
Telehealth continues to increase in men’s hormone care as patients seek faster evaluation and more flexible access to licensed clinicians. Integrated care models allow clinicians to assess laboratory data remotely, prescribe treatment, and follow up with patients.

Media Contact: Thomas Phillips, support@feel30.com, 833-545-1589

**About Feel30** Feel30 is based in Austin, Texas. The platform provides evidence-based testosterone therapy, enclomiphene treatment, and men’s health services with all-inclusive pricing, at-home lab testing with nurse visits, unlimited clinician support, and fast U.S. pharmacy fulfillment. The company’s mission is to make evidence-based hormone care clearer, faster, and more accessible for busy men nationwide who refuse to wait.

Cision View original content:https://www.prnewswire.com/news-releases/feel30-launches-austin-based-telehealth-platform-for-evidence-proven-trt–integrated-at-home-phlebotomy-services-302646836.html

SOURCE Feel30

Market Opportunity
TRUST AI Logo
TRUST AI Price(TRT)
$0.2682
$0.2682$0.2682
+9.33%
USD
TRUST AI (TRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Huawei goes public with chip ambitions, boosting China’s tech autonomy post-Nvidia

Huawei goes public with chip ambitions, boosting China’s tech autonomy post-Nvidia

The post Huawei goes public with chip ambitions, boosting China’s tech autonomy post-Nvidia appeared on BitcoinEthereumNews.com. Huawei publicly revealed its full chip roadmap on Thursday during its annual Connect conference in Shanghai, confirming it would begin releasing some of the world’s most powerful computing systems in a push to reduce China’s reliance on Nvidia and other foreign chipmakers, according to Reuters. Eric Xu, Huawei’s rotating chairman, disclosed that the company had developed its own high-bandwidth memory, a technology previously led by Samsung and SK Hynix. Xu said, “We will follow a 1-year release cycle and double compute with each release,” making it clear Huawei now intends to release next-gen chips and hardware annually with increased processing capabilities. The announcement came just days before U.S. President Donald Trump and Chinese President Xi Jinping are expected to meet on Friday, following trade talks between both countries earlier in the week. The move is widely seen as an attempt by Beijing to project confidence in its tech ecosystem as U.S.-China tensions continue to grow. Huawei releases full schedule for Ascend, Kunpeng chips, and computing clusters Huawei detailed the timeline for its AI chip series Ascend, starting with the 910C, which was released earlier this year. The Ascend 950 will launch in 2026 with two variants. The 960 will follow in 2027, and the 970 is scheduled for 2028. Huawei also confirmed its Kunpeng server chips will receive updates in 2026 and 2028. China’s chip war with the U.S. escalated this week as Nvidia was accused of violating China’s anti-monopoly law, and several large Chinese tech firms were ordered to cancel Nvidia AI chip orders. Financial Times reported that government regulators had also instructed distributors to stop placing new Nvidia orders. One executive in China’s chip distribution industry said his company was told verbally to stop buying Nvidia chips and was only allowed to sell current inventory. That executive declined…
Share
BitcoinEthereumNews2025/09/18 21:20
Whales keep selling XRP despite ETF success — Data signals deeper weakness

Whales keep selling XRP despite ETF success — Data signals deeper weakness

The post Whales keep selling XRP despite ETF success — Data signals deeper weakness appeared on BitcoinEthereumNews.com. XRP ETFs have crossed $1 billion in assets
Share
BitcoinEthereumNews2025/12/20 02:55
Foreigner’s Lou Gramm Revisits The Band’s Classic ‘4’ Album, Now Reissued

Foreigner’s Lou Gramm Revisits The Band’s Classic ‘4’ Album, Now Reissued

The post Foreigner’s Lou Gramm Revisits The Band’s Classic ‘4’ Album, Now Reissued appeared on BitcoinEthereumNews.com. American-based rock band Foreigner performs onstage at the Rosemont Horizon, Rosemont, Illinois, November 8, 1981. Pictured are, from left, Mick Jones, on guitar, and vocalist Lou Gramm. (Photo by Paul Natkin/Getty Images) Getty Images Singer Lou Gramm has a vivid memory of recording the ballad “Waiting for a Girl Like You” at New York City’s Electric Lady Studio for his band Foreigner more than 40 years ago. Gramm was adding his vocals for the track in the control room on the other side of the glass when he noticed a beautiful woman walking through the door. “She sits on the sofa in front of the board,” he says. “She looked at me while I was singing. And every now and then, she had a little smile on her face. I’m not sure what that was, but it was driving me crazy. “And at the end of the song, when I’m singing the ad-libs and stuff like that, she gets up,” he continues. “She gives me a little smile and walks out of the room. And when the song ended, I would look up every now and then to see where Mick [Jones] and Mutt [Lange] were, and they were pushing buttons and turning knobs. They were not aware that she was even in the room. So when the song ended, I said, ‘Guys, who was that woman who walked in? She was beautiful.’ And they looked at each other, and they went, ‘What are you talking about? We didn’t see anything.’ But you know what? I think they put her up to it. Doesn’t that sound more like them?” “Waiting for a Girl Like You” became a massive hit in 1981 for Foreigner off their album 4, which peaked at number one on the Billboard chart for 10 weeks and…
Share
BitcoinEthereumNews2025/09/18 01:26